Share on LinkedInShare on LinkedIn

ARTICLE · 29 MARCH 2024

Court Of Appeal Summaries (March 25 – 29, 2024)

Blaney McMurtry LLP
Blaney McMurtry LLP
Contributor
Explore more from Blaney McMurtry LLP

Palmer v. Teva Canada Limited was a proposed class action against several pharmaceutical companies for negligently manufacturing contaminated valsartan, a medication for high blood pressure.

CanadaLitigation, Mediation & Arbitration

Palmer v. Teva Canada Limited was a proposed class action against several pharmaceutical companies for negligently manufacturing contaminated valsartan, a medication for high blood pressure. The plaintiffs sought damages for potential increased cancer risk, medical costs, refunds, and psychological harm. The motion judge dismissed the certification motion, finding that the claims lacked viability due to speculative harm and failed on the commonality and preferability tests for certification. The appeal was dismissed, affirming that without tangible harm, such as physical injury, psychological distress, or economic loss, the claims were not compensable in tort law. The appellants' assertions of genotoxic injury and psychological harm lacked material facts supporting compensable damages. Moreover, claims for economic loss were deemed insufficient due to the absence of imminent danger and failure to address potential harm from the contaminated product. Other claims under

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be ought about your specific circumstances.

See more popular content from